Related Experiment Video
Updated: Jul 8, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
MTHFR gene polymorphism and diabetic retinopathy.
Makiko Maeda1, Yasushi Fujio, Junichi Azuma
1Department of Clinical Evaluation of Medicines and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, Japan.
Current Diabetes Reviews
|January 29, 2008
Summary
Methylenetetrahydrofolate reductase (MTHFR) gene variations can worsen diabetic retinopathy (DR) progression, especially with poor blood sugar control. Lowering homocysteine may help prevent DR development and progression.
Area of Science:
- Ophthalmology
- Genetics
- Endocrinology
Background:
- Diabetic retinopathy (DR) is a leading cause of vision loss, exacerbated by hyperglycemia and other vascular risk factors.
- Methylenetetrahydrofolate reductase (MTHFR) gene polymorphism (C677T) impairs enzyme activity, leading to hyperhomocysteinemia, a risk factor for macroangiopathy.
- Hyperhomocysteinemia is increasingly implicated in the progression of DR, a microangiopathic complication of diabetes.
Purpose of the Study:
- To investigate the role of MTHFR gene polymorphism in diabetic retinopathy progression.
- To explore the link between hyperhomocysteinemia, vascular inflammation, and DR.
- To propose personalized medicine strategies for diabetes mellitus based on MTHFR genetics.
Main Methods:
- Review of clinical studies examining MTHFR gene polymorphism and DR.
- Analysis of the relationship between homocysteine levels, inflammatory cytokines (e.g., VEGF), and DR.
- Exploration of the potential impact of homocysteine reduction on DR development.
Main Results:
- MTHFR gene polymorphism is associated with DR progression, particularly in patients with uncontrolled blood glucose.
- Homocysteine activates vascular inflammation via inflammatory cytokines like VEGF.
- Decreased plasma homocysteine levels may prevent DR development and progression.
Conclusions:
- MTHFR gene polymorphism is a significant factor in diabetic retinopathy progression.
- Managing homocysteine levels presents a potential therapeutic target for preventing DR.
- Understanding MTHFR genetics could enable personalized medicine approaches for diabetic patients.
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...